Health Care
Automotive

In health care today, scientific and technological frontiers are expanding at unprecedented rates—even as economic and financial pressures shrink profit margins, intensify competition, and constrain the funds available for investment.

China’s huge medical needs, rapid economic growth, large talent pool, and maturing regulatory environment have all attracted global attention. The players that wish to better position themselves for survival and, ultimately, success in the years ahead need to act now if they are to thrive in the Chinese market.

BCG’s Health Care practice is one of the most important pillars in the firm’s global business, and contributes significantly to the growth of BCG in Greater China. Our Greater China Health Care practice has garnered trust from a wide range of clients due to its long history, strong presence in the region, and unparalleled experience in both global and local health care. We have a large dedicated health care consulting team in Greater China, including three partners, and seven principals and project leaders with expertise in all aspects of health care and related client issues.

Our Greater China Health Care practice has a long tradition of pioneering new concepts and formulating novel business strategies. The practice’s leading-edge research and publications have significant influence in China’s health care industry. The team has worked on a broad array of health care-related projects in numerous functional areas, including:

  • Strategy
  • Value-chain processes
  • Research and product development
  • Marketing and sales
  • Operations
  • Information technology
  • Organizational effectiveness
  • Corporate development and postmerger integration
  • Regulatory management

We also maintain productive working relationships with clients in a range of health care-related specialties:

  • Pharmaceuticals (both prescription and OTC)
  • Biotechnology
  • Health care nutrition
  • Medical technology (including medical equipment and medical devices)
  • Payers
  • Providers
  • Trusts, foundations, and industry associations

 

Rachel Lee
Partner & Managing Director
Shanghai
+86 21 2306 4000 		Carol Liao
Partner & Managing Director
Hong Kong
+852 2506 2111
Ted Chan
Partner & Managing Director
Hong Kong
+852 2506 2111 		John Wong
Senior Partner & Managing Director
Hong Kong
+852 2506 2111

Publications


July, 2002
[PDF]China's Growing Drug Market: Will You Be a Contender?

Several powerful forces over the next five to ten years will expand the pharmaceutical opportunity in China for foreign players. Indeed, by 2010 we expect China to emerge as the fourth largest pharmaceutical market in the world. The two most promising opportunities will emerge in the areas of greatest unmet need: sophisticated, innovative, ethical drugs and differentiated OTC products. Best poised to fill these future needs are multinational companies.



BCG in the News


February 05, 2009
The Economist
The Unrepentant Salesman
Rachel Lee of the Boston Consulting Group thinks firms like AstraZeneca bring much-needed professionalism to China’s drugs industry, once dominated by local generics firms notorious for relying on cronyism and kickbacks. Western firms are, she suggests, thus helping Chinese doctors shift towards “evidence based” medicine.


  • Wealth Markets in China: Seeking the Opportunity to LeadMore
  • The World’s Next E-Commerce Superpower: Navigating China’s Unique Online-Shopping EcosystemMore
  • The Dragon Wants to Spend: Turning the Corner on Consumer Lending in ChinaMore
  • Dressing Up: Capturing the Dynamic Growth of China’s Fashion MarketMore
  • Navigating the New Consumer Realities: Consumer Sentiment 2011More